PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2183484
PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2183484
The global immunoassay market is estimated to be valued at USD 31.65 billion in 2026 and is projected to reach USD 44.49 billion by 2031, registering a CAGR of 7.0% during the forecast period.
| Scope of the Report | |
|---|---|
| Years Considered for the Study | 2026-2031 |
| Base Year | 2025 |
| Forecast Period | 2026-2031 |
| Units Considered | Value (USD billion) |
| Segments | By Product, By Technology, By Specimen, By Application, By End User, Region |
| Regions covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
Market growth is primarily driven by the rising prevalence of chronic and infectious diseases, continued technological advancements in immunoassay systems, supportive government initiatives, and increasing demand for drug and alcohol screening driven by stringent regulatory requirements.

"By product, the reagents & kits segment accounted for the largest share of the immunoassay market in 2025."
Based on product type, the global immunoassay market is segmented into reagents & kits and analyzers. Among these, reagents & kits are expected to account for the largest share of the market, primarily owing to their recurring use across a broad range of diagnostic applications. The growing volume of immunoassay testing, coupled with the continuous requirement for consumable reagents and kits, supports sustained demand for this segment. In addition, the increasing availability of high-performance products that offer enhanced diagnostic accuracy, reliability, and workflow efficiency is contributing to their widespread adoption and supporting segment growth.
"By technology, the chemiluminescence immunoassay segment is expected to grow at a considerable rate during the forecast period."
The immunoassay market is segmented by technology into ELISA, chemiluminescence immunoassay (CLIA), immunofluorescence assay (IFA), rapid tests, ELISpot, western blotting, and other technologies. Among these, the CLIA segment is expected to grow significantly during the forecast period, driven by its increasing adoption in diagnosing and monitoring chronic and infectious diseases. CLIA offers several advantages over conventional techniques, including high sensitivity and specificity, a broad dynamic range, faster turnaround times, and lower background interference. These benefits, along with its suitability for automated and high-throughput testing, are expected to support the increasing adoption of CLIA in clinical diagnostic applications.
"Asia Pacific is expected to register the fastest growth rate in the immunoassay market between 2026 and 2031."
The global immunoassay market is segmented geographically into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Among these regions, Asia Pacific is expected to register the highest growth during the 2026-2031 forecast period. This growth is attributed to the region's large and expanding patient population, increasing prevalence of chronic and infectious diseases, growing awareness of early disease diagnosis, and continued improvements in healthcare infrastructure. In addition, increasing healthcare investments and the adoption of advanced diagnostic technologies across countries such as China, India, and Southeast Asian nations are expected to further support market growth in the region.
Key players in the immunoassay market are Abbott Laboratories (US), F. Hoffmann-La Roche Ltd (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), PerkinElmer, Inc. (US), Becton, Dickinson and Company (US), DiaSorin S.p.A. (Italy), Bio-Rad Laboratories, Inc. (US), QuidelOrtho Corporation (US), bioMerieux (France), QIAGEN N.V. (Germany), Sysmex Corporation (Japan), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China), Agilent Technologies (US), Merck KGaA (Germany), Meridian Bioscience (US), Bio-Techne (US), Cellabs (Australia), Abnova Corporation (Taiwan), J. Mitra & Co. Pvt. Ltd. (India), Tosoh Corporation (Japan), Cell Sciences (US), Enzo Biochem (US), Creative Diagnostics (US), Boster Biological Technology (US), Elabscience (US), WAK-Chemie Medical GmbH (Germany), SeraCare (US), Epitope Diagnostics Inc. (US), Kamiya Biomedical Company (US), Gyros Protein Technologies (Sweden), Trivitron Healthcare (India), InBios International Inc. (US), and Maccura Biotechnology Co., Ltd. (China).
This research report categorizes the immunoassay market by product (reagents & kits and analyzers), specimen type (blood, urine, saliva, and other specimens), technology (enzyme-linked immunosorbent assays, rapid tests, chemiluminescence immunoassay, immunofluorescence assay, enzyme-linked immunospot, western blotting, and other technologies), application (infectious diseases, blood screening, oncology, endocrinology, bone and mineral disorders, autoimmune disorders, cardiology, drug monitoring and testing, allergy diagnostics, newborn screening, and other applications), end user (clinical laboratories, hospitals & clinics, blood banks, and home care settings), and region (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America).
The report covers detailed information on major factors, such as drivers, restraints, opportunities, and challenges influencing immunoassay market growth. A detailed analysis of key industry players provides insights into their business overview, solutions, and key strategies, including partnerships, collaborations, expansions, agreements, product launches, and recent market developments. This report covers the competitive analysis of upcoming startups in the immunoassay ecosystem.
The report will help leaders/new entrants in this market by providing revenue estimates for the overall immunoassay market and its subsegments. This report will help stakeholders understand the competitive landscape and gain deeper insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key drivers, restraints, opportunities, and challenges.